Date: 2014-12-03
Type of information: Series B financing round
Company: Anergis (Switzerland)
Investors: Vinci Capital-Renaissance PME (Switzerland) BioMedInvest (Switzerland) Sunstone Capital ( Denmark) Esperante (Sweden) Initiative Capital Romandie (Switzerland) WJFS (USA)
Amount: CHF 14.5 Million (€ 12.1 million)
Funding type: series B financing round
Planned used: The funds will be used to advance Anergis´ birch allergy vaccine AllerT closer to market. The company is currently preparing the Phase III clinical trial program of AllerT. Anergis has already demonstrated the rapid and long-lasting clinical efficacy of AllerT in two subsequent field-based clinical Phase II trials. The funds will also be used to advance the AllerR ragweed allergy program towards clinical testing, as well as to research and discover undisclosed new Contiguous Overlapping Peptide (COP) allergy vaccines.
Others: * On December 3, 2014, Anergis, a company developing proprietary ultra-fast allergy vaccines,announced the closing of a Series B financing round totaling CHF 14.5 million (€ 12.1 million, $ 15 million). All Series A investors participated in the round together with new private European and U.S.-based investors. The financing was jointly led by existing investors Sunstone Capital, BioMedInvest and Renaissance PME as well as new investor WJFS, Inc. Anergis has so far raised a total of CHF 44 million in private equity, which includes the latest Series B financing round.
Therapeutic area: Allergic diseases - Immunological diseases
